N-[(2R,3R,5S)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide | 72-87-7

• 物质功能分类: 生物化工 - 糖类化合物 - 单糖
• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-[(2R,3R,5S)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
• CAS: 72-87-7；1136-42-1；1136-44-3；6082-29-7；6730-06-9；7772-94-3；10036-64-3；14131-60-3；14131-64-7；14131-68-1；14215-68-0；62057-49-2；62057-50-5；62057-51-6；62057-52-7；62057-53-8；62057-54-9；62057-55-0；62057-56-1；62075-50-7；62137-54-6；134451-97-1；134522-12-6；148347-16-4
• 化学式: C₈H₁₅NO₆
• 分子量: 221.21
• InChiKey: OVRNDRQMDRJTHS-DJSSTOROSA-N

物化性质

• 熔点：
  211 °C
• 沸点：
  595.4±50.0 °C(Predicted)
• 密度：
  1.50
• LogP：
  -2.314 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  119
• 氢给体数：
  5
• 氢受体数：
  6

制备方法与用途

该化合物2-乙酰氨基-2-脱氧-α-D-吡喃葡萄糖主要用于科研。

文献信息

• CHEMOSELECTIVE LIGATION
  申请人：SAXON Eliana

  公开号：US20070037964A1

  公开（公告）日：2007-02-15

  The present invention features a chemoselective ligation reaction that can be carried out under physiological conditions. In general, the invention involves condensation of a specifically engineered phosphine, which can provide for formation of an amide bond between the two reactive partners resulting in a final product comprising a phosphine moiety, or which can be engineered to comprise a cleavable linker so that a substituent of the phosphine is transferred to the azide, releasing an oxidized phosphine byproduct and producing a native amide bond in the final product. The selectivity of the reaction and its compatibility with aqueous environments provides for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).

  本发明涉及一种可以在生理条件下进行的化学选择性连接反应。一般来说，该发明涉及特定设计的膦化合物的缩合作用，该膦化合物可以提供两个反应物之间的酰胺键形成，从而产生一个包含膦基团的最终产物，或者可以被设计成包含可裂解的连接剂，使膦的取代基转移到叠氮化合物上，释放出一个氧化膦副产物，并在最终产物中产生一个天然的酰胺键。该反应的选择性及其与水性环境的兼容性使其可以应用于体内（例如在细胞表面或细胞内）和体外（例如合成肽和其他聚合物，生产改性（例如标记）氨基酸）。
• N-ACETYL MANNOSAMINE AS A THERAPEUTIC AGENT
  申请人：the Secretary of the Department of Health and The Government of the United States of America as represented by

  公开号：US20130196936A1

  公开（公告）日：2013-08-01

  The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.
• US20140271615A1
  申请人：——

  公开号：US20140271615A1

  公开（公告）日：2014-09-18
• N-ACETYL MANNOSAMMINE AS A THERAPEUTIC AGENT
  申请人：The United States of America, as represented by the Secretary, Department of Health and Human Serv

  公开号：US20150290229A1

  公开（公告）日：2015-10-15

  The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.
• HYPOSIALYLATION DISORDERS
  申请人：THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SER

  公开号：US20160025717A1

  公开（公告）日：2016-01-28

  Methods are disclosed for diagnosing a hyposialylation disorder. Methods are also disclosed for determining the effectiveness of a therapeutic agent for treatment of a hyposialylation disorder in a subject. These methods include measuring an amount of monosialylated Thomsen-Friedenreich (ST) antigen and measuring an amount of non-sialylated Thomsen-Friedenreich antigen (T) in a biological sample, such as a serum or plasma sample from the subject, and determining the ratio of T to ST.

表征谱图